Sofinnova Partners (FR)
Denis Lucquin is a Managing Partner and Chairman of Sofinnova Partners who specialises in
life sciences, and industrial biotech investments.
He joined Sofinnova in 1991. Denis began
his career in academic research. For five years, he was in charge of the technology transfer
department at the Institut National de la Recherche Agronomique (INRA), France's
agricultural research institute.
In 1989, he joined the venture capital industry as director of
investments at Innolion (Crédit Lyonnais).
He carried out many investments in Europe such as Nicox, Oxford Glycosciences, Oxford
Molecular, PPL Therapeutics, Conjuchem, Exonhit, IDM, Innate Pharma and Ablynx (all of
which successfully went public) and Novexel (sold to Astrazeneca), and Crop Design,
Cerenis, and Noxxon.
He recently invested in BioAmber, a developer of innovative
technologies for molecules to the chemical industry. He actively supports all of these
companies and acts or as acted as a board member for most of them.
He is also a founder of
Association France Biotech. He is a graduate in engineering from Ecole Polytechnique and
Ecole du Génie Rural des Eaux et Forêts. He also has a degree in Innovation Management
from the Université de Paris-Dauphine.